PeopleBio Inc

Capital Structure and Liquidity PeopleBio Inc has a debt-to-equity ratio of 0.27, indicating a relatively low level of leverage. However, the company's current ratio of 0.31 suggests significant liquidity constraints, as current assets are insufficient to cover current liabilities. The company's cash and equivalents amount to 80,099,980 KRW, which is far below the total liabilities of 15,953,576,140 KRW, resulting in a negative net cash position after subtracting total debt. ### Profitability and Returns The company is currently unprofitable, with a net income of -15,713,964,040 KRW and a return on equity of -0.5491. The return on assets is also negative at -0.3526, indicating that the company is not generating returns that cover its cost of capital. These metrics are below the industry median for profitability and returns, reflecting operational inefficiencies and potential challenges in scaling the business. ### Segments and Geographic Exposure PeopleBio Inc operates in a single disclosed segment focused on blood diagnostic products. The company sells its products in both domestic and overseas markets, but the financial data does not provide a breakdown of revenue by geographic region. This lack of segmentation detail limits the ability to assess geographic concentration risk. ### Growth Trajectory The company's recent financial performance shows a decline in operating income and net income, with no clear indication of a turnaround in the near term. The capital expenditure of -323,777,320 KRW suggests some investment in growth, but the negative free cash flow of -11,122,446,380 KRW indicates that the company is not generating sufficient cash to fund operations or expansion without external financing. ### Risk Factors The company faces medium liquidity risk due to its low current ratio and negative net cash position. The risk assessment also flags the potential for dilution, although it is currently rated as low. The company's unprofitability and negative cash flows increase the likelihood of needing additional financing, which could lead to equity dilution or increased debt. ### Recent Events Recent financial filings indicate continued losses and negative cash flows, with no significant events or strategic announcements reported in the latest disclosures. The company's focus remains on its core diagnostic products, but there is no indication of new product launches or market expansion initiatives in the recent data.